Market revenue in 2021 | USD 5.0 million |
Market revenue in 2032 | USD 29.5 million |
Growth rate | 17.5% (CAGR from 2021 to 2032) |
Largest segment | Chronic immunomodulators |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 32% in 2021. Horizon Databook has segmented the Argentina myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
According to a study published in European Neurology, in Argentina, around 73.7% of patients develop generalized MG (gMG), while others displayed only ocular symptoms throughout the disease.
Furthermore, according to data published by New York Academy of Sciences, generic drugs that are most commonly used for the treatment of MG in Argentina may not have the same therapeutic effect as branded drugs, which may sometimes lead to increased usage of high steroid doses.
Government support to improve healthcare system and enhanced access to advance diagnosis & treatment are expected to fuel market growth in Argentina However, limited affordability of MG treatment and low diagnosis rate of MG in the country are expected to hamper market growth during the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Argentina myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account